Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Acquisitions of early-stage assets, biotech platforms and capabilities like AI are the way to faster growth for pharma companies, as Accenture’s Petra Jantzer told In Vivo. However, changing the focus of M&A away from conventional late-stage assets requires significant shifts in corporate and R&D culture.
In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in July 2022. Data provided by Biomedtracker.
Pharma's commercial workforce is engaging with its customers in a myriad of new ways, all of them fueled by digital. These efforts must be co-ordinated, and embrace news ways of working if they are to succeed.
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
A selection of articles you might have missed from July 2022, including an exploration of this year's top selling drugs, an in depth discussion about how life sciences leadership is changing, as well as a look into AC Immune's Parkinson's research.
Sharing his thoughts on the European funding landscape, the importance of software, and sustainable investments, INKEF Capital’s Thijs Cohen Tervaert talks to In Vivo about his investment priorities.
Costly delays can come from mismanaged clinical trial processes. Consolidation is vital when managing multiple vendors, and study sites, to ensure your team does not drop the ball.
This article reveals the top 10 pharmaceutical products by revenues in 2022 and discusses the major themes affecting the highest-grossing drugs and the companies behind their continued development.
Rising leader Mårten Steen, spoke with In Vivo about translating science into business, building precision medicine firms from the ground up and the importance of high-energy leadership.
Swiss-based Rejuveron’s diversified platform of longevity biotechs addresses key hallmarks of aging, with the goal of helping people to age better and live longer with reduced burden of age-related diseases. CEO Matthias Steger discusses the firm’s vision and the road ahead.
Publisher’s Spotlight: Citeline, the publisher of In Vivo, is to merge with fellow pharmaceutical solutions provider Norstella.
A selection of articles you might have missed from June 2022, including a deep dive into venture finance, an in depth discussion about Russia's upcoming drug supply woes, and the latest Rising Leaders interviews.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.